Fortress Biotech 9.375% Cum Red Per Pref Ser A Usd25.00 (FBIOP) Stock
Small biotech company developing new drug candidates. Here's the price, business snapshot, and what's worth knowing about Fortress Biotech 9.375% Cum Red Per Pref Ser A Usd25.00 in October 2026.
FBIOP is a ticker for a smaller biotechnology/biopharmaceutical issuer. Investors considering this stock should know it is typically driven by the progress of clinical programmes, regulatory decisions and partner or licensing deals rather than steady revenue streams. Small-cap biotech stocks can offer significant upside if a drug candidate succeeds, but they also carry elevated risks: trial failures, regulatory setbacks, dilution from financing and thin trading liquidity can cause sharp share-price moves. Research should start with the company’s latest filings, clinical timelines, cash runway and management experience, and be supplemented by reputable news and analyst coverage. Portfolio allocation matters: biotech exposure is often suited to investors who accept higher volatility and can tolerate potential loss of capital. This information is educational and not financial advice — consider seeking a regulated financial adviser before making investment decisions, and remember past performance is not a reliable indicator of future results.
About This Stock
FORTRESS BIOTECH INC 9.375% CUM RED PER PREF SER A USD25.00
FBIOP
Current Price
$16.86
Potential 12 Month Profit
N/A
Sector
N/A
Industry
N/A
Ticker
FBIOP
Market Cap
N/A
Potential 12 Month Profit
N/A
Sector
N/A
Industry
N/A
Sixth Month Growth Performance
Stock Performance Snapshot
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical catalysts ahead
Trial readouts and regulatory steps can drive large share movements, though outcomes are uncertain and can move the price sharply in either direction.
Funding and dilution
Small biotechs often need fresh capital; watch cash runway and financing announcements as they can dilute shareholders and change risk profiles.
Regulatory and partnerships
Approvals, licensing deals or strategic partnerships can materially affect prospects, but regulatory pathways are complex and outcomes are not guaranteed.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.